[go: up one dir, main page]

BRPI0507852A - 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas - Google Patents

2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas

Info

Publication number
BRPI0507852A
BRPI0507852A BRPI0507852-0A BRPI0507852A BRPI0507852A BR PI0507852 A BRPI0507852 A BR PI0507852A BR PI0507852 A BRPI0507852 A BR PI0507852A BR PI0507852 A BRPI0507852 A BR PI0507852A
Authority
BR
Brazil
Prior art keywords
pyrimidin
pyridin
pyrido
ylamino
ones
Prior art date
Application number
BRPI0507852-0A
Other languages
English (en)
Inventor
Mark Robert Barvian
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0507852A publication Critical patent/BRPI0507852A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

2-(PIRIDIN-3-ILAMINO)-PIRIDO<sym2,3-d>PIRIMIDIN-7-ONAS. A presente invenção refere-se a compostos de fórmula l: onde R¬ 1¬,R¬ 2¬,R¬ 3¬,R¬ 4¬ e X¬ 1¬ são como definidos no relatório descritivo. Os compostos de fórmula l do tipo 2-(piridin-3-ilamino)-pirido<sym2,3-d>pirimidin-7-ona, que são inibidores das cinases dependentes de ciclina 2 e 4 (Cdk2 e Cdk4), são úteis no tratamento de distúrbios de proliferação celular.
BRPI0507852-0A 2004-02-18 2005-02-07 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas BRPI0507852A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54536104P 2004-02-18 2004-02-18
PCT/IB2005/000300 WO2005082903A1 (en) 2004-02-18 2005-02-07 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones

Publications (1)

Publication Number Publication Date
BRPI0507852A true BRPI0507852A (pt) 2007-07-10

Family

ID=34910727

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507852-0A BRPI0507852A (pt) 2004-02-18 2005-02-07 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas

Country Status (6)

Country Link
US (1) US20050182078A1 (pt)
EP (1) EP1718645A1 (pt)
JP (1) JP2007523151A (pt)
BR (1) BRPI0507852A (pt)
CA (1) CA2555724A1 (pt)
WO (1) WO2005082903A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
MX2009002927A (es) 2006-09-15 2009-03-31 Pfizer Prod Inc Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3.
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
CN101535308A (zh) * 2006-11-09 2009-09-16 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的取代的6-苯基-吡啶并[2，3-d]嘧啶-7-酮衍生物及其使用方法
KR101626435B1 (ko) * 2007-04-10 2016-06-01 엑셀리시스, 인코포레이티드 Ｐｉ３ｋ 알파의 피리도피리미디논 억제제를 이용한 암 치료 방법
MX2010006457A (es) * 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
CA2719538C (en) * 2008-04-07 2014-03-18 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2350070A1 (en) 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor
WO2010071846A2 (en) * 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
JP2013507395A (ja) * 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
KR101754664B1 (ko) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
US8680099B2 (en) * 2010-06-10 2014-03-25 Afraxis Holdings, Inc. 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
EA022527B1 (ru) 2010-08-05 2016-01-29 Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
DK2688887T3 (en) 2011-03-23 2015-06-29 Amgen Inc DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
CN108191857B (zh) * 2017-01-24 2020-10-23 晟科药业（江苏）有限公司 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN111032655B (zh) 2017-08-31 2022-09-02 达纳-法伯癌症研究所股份有限公司 Egfr和/或her2抑制剂和使用方法
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020006210A1 (en) * 2018-06-27 2020-01-02 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MX2022004390A (es) * 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR125798A1 (es) 2021-05-07 2023-08-16 Kymera Therapeutics Inc Degradadores cdk2 y usos de los mismos
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6420384B2 (en) * 1999-12-17 2002-07-16 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
EP1255755A1 (en) * 2000-01-27 2002-11-13 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
AU2001298008A1 (en) * 2000-08-04 2003-04-07 Warner-Lambert Company Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido (2,3-d)pyrimidin-7-ones
US6960662B2 (en) * 2000-08-04 2005-11-01 Warner-Lambert Company Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES

Also Published As

Publication number Publication date
EP1718645A1 (en) 2006-11-08
CA2555724A1 (en) 2005-09-09
US20050182078A1 (en) 2005-08-18
JP2007523151A (ja) 2007-08-16
WO2005082903A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
BRPI0507852A (pt) 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
WO2008115369A3 (en) Inhibitors of focal adhesion kinase
BR0307057A (pt) 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
MY169791A (en) Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
WO2008121687A3 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
TW200616623A (en) Organic compounds
TW200611898A (en) Organic compounds
NO20085331L (no) Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
BR112013012502A2 (pt) pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
NO20082091L (no) Nye pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
NZ599932A (en) Imidazopyridine derivatives as jak inhibitors
BRPI0507644B8 (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
WO2008150446A8 (en) Inhibitors of protein kinases
WO2009021169A3 (en) (7h-pyrr0l0 [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
BR112012010041A2 (pt) derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10
WO2008078100A3 (en) Tricyclic amine derivatives as protein tyrosine kinase inhibitors
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
WO2007117995A3 (en) Kinase inhibitors
TW200608978A (en) Organic compounds
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.